FlashFeed

Eli Lilly to File for Approval of Next-Gen Obesity Drug Retatrutide in 2027

Eli Lilly announced it will file for regulatory approval of retatrutide, its next-generation obesity drug, in 2027 after positive results from five late-stage clinical trials. The drug, dubbed a "triple-G" agonist, is being positioned as the next pillar of Lilly's obesity portfolio alongside tirzepatide. Results across trials consistently show high efficacy in reducing body weight.